Tafinlar (dabrafenib) — Cigna
Thyroid Carcinoma, Differentiated
Initial criteria
- Patient has differentiated thyroid carcinoma (examples include papillary, follicular, and oncocytic thyroid carcinoma)
- Patient has recurrent or metastatic disease
- Patient has BRAF V600 mutation-positive disease
Approval duration
1 year